Zynex
8022 Southpark Circle
Suite 100
Littleton
Colorado
80120
United States
Tel: 303-703-4906
Fax: 800-495-6695
260 articles about Zynex
-
Zynex Reports Fourth Quarter and Full Year 2023 Financial Results
2/29/2024
Zynex, Inc. (NASDAQ: ZYXI) today reported its financial and operational results for the fourth quarter and full year ended December 31, 2023 and its Board of Directors has approved an additional program to repurchase up to $20.0 million of the Company's common stock.
-
Zynex Sets Fourth Quarter and Full Year 2023 Earnings Call
2/22/2024
Zynex, Inc. will hold a conference call on Thursday, February 29, 2024 at 4:15 PM Eastern Time to discuss its financial results for the fourth quarter and full year ended December 31, 2023.
-
Zynex Introduces New Products
2/20/2024
Zynex, Inc. introduced two new therapy products: the Zynex Pro Hybrid LSO and the Zynex DynaComp Cold Compression.
-
Zynex Receives FDA Clearance for its Next Generation NMES Device
2/6/2024
Zynex, Inc today announced that it has received clearance from the U.S. Food and Drug Administration ("FDA") for the next generation M-Wave Neuromuscular Electrical Stimulation ("NMES") device.
-
Zynex Recognized in Top 25 Medical Device Companies for 2024
2/2/2024
Zynex, Inc. announced The Healthcare Technology Report recognized Zynex as 9th amongst the Top 25 Medical Device Companies for 2024.
-
Zynex to Participate at the Needham Annual Growth Conference
1/8/2024
Zynex, Inc. announced it will participate virtually in the upcoming Needham Annual Growth Conference, which is being held January 16th-19th, 2024.
-
Zynex Ranked in Forbes List of "America's Most Successful Small-Cap Companies 2024"
11/15/2023
Zynex, Inc. announced the Company has been ranked within Forbes' list of America's Most Successful Small-Cap Companies for 2024.
-
Zynex Submits FDA Application for its Next Generation NMES Device
11/13/2023
Zynex, Inc. announced that it has submitted a 510 application to the U.S. Food and Drug Administration for the M-Wave Neuromuscular Electrical Stimulation device.
-
Zynex Named as a Winner in the Deloitte 2023 Technology Fast 500 Awards for the 5th Consecutive Year
11/9/2023
Zynex, Inc., an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced the Company has been ranked among all companies in the U.S. and Canada between 2019 and 2022 on Deloitte's Technology Fast 500.
-
Zynex Announces Share Repurchase Program - November 01, 2023
11/1/2023
Zynex, Inc. announced that its board of directors approved a program to repurchase up to $20.0 million of the Company's common stock.
-
Zynex Announces Review of Strategic Alternatives
10/31/2023
Zynex, Inc. announced its Board of Directors has initiated a process to evaluate potential strategic alternatives to maximize shareholder value.
-
Zynex Reports Third Quarter 2023 Financial Results
10/26/2023
Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has reported its financial and operational results for the third quarter ended September 30, 2023.
-
Zynex, Inc Sets Third Quarter 2023 Earnings Call
10/12/2023
Zynex, Inc. (NASDAQ: ZYXI) will hold a conference call on Thursday, October 26, 2023 at 4:15 PM Eastern Time to discuss its financial results for the third quarter ended September 30, 2023.
-
Zynex to Present at the Cantor Global Healthcare Conference
9/19/2023
Zynex, Inc. announced it will present at the upcoming Cantor Global Healthcare Conference, which is being held September 26th -28th, 2023.
-
Zynex Announces Share Repurchase Program
9/11/2023
Zynex, Inc today announced that its board of directors approved a program to repurchase $10.0 million of the Company's common stock.
-
Zynex Announces 1 Millionth Patient Milestone
8/10/2023
Zynex, Inc., an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced that, since its founding, the company has treated more than 1 million patients through its pain management division.
-
Zynex, Inc Announces New Therapy Products
8/9/2023
Zynex, Inc., an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced the addition of three new therapy products centered around pain management.
-
Zynex, Inc Founder and CEO Thomas Sandgaard to participate in Benzinga's Pharma Companies vs. A Tough Macro Backdrop Free Webinar on August 3rd at 12:15 PM ET
8/3/2023
Zynex, Inc. has the company's Founder and CEO, Thomas Sandgaard will participate in Benzinga's Pharma Companies vs. A Tough Macro Backdrop Free Webinar at 12:15 PM ET on August 3rd, 2023.
-
Zynex Reports Second Quarter 2023 Financial Results
7/27/2023
Zynex, Inc. (Nasdaq: ZYXI) has reported its financial and operational results for the second quarter ended June 30, 2023.
-
Zynex, Inc. Sets Second Quarter 2023 Earnings Call
7/20/2023
Zynex, Inc. will hold a conference call on Thursday, July 27, 2023 at 4:15 PM Eastern Time to discuss its financial results for the second quarter, 2023 ended June 30, 2023.